Savant Capital LLC Sells 752 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Savant Capital LLC lessened its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 20.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,864 shares of the medical research company’s stock after selling 752 shares during the quarter. Savant Capital LLC’s holdings in Exact Sciences were worth $212,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in EXAS. Valley National Advisers Inc. boosted its holdings in Exact Sciences by 29.5% during the third quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 176 shares during the period. Cullen Frost Bankers Inc. boosted its stake in Exact Sciences by 40.0% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 700 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 200 shares during the period. Nisa Investment Advisors LLC grew its holdings in Exact Sciences by 0.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 37,200 shares of the medical research company’s stock valued at $2,752,000 after buying an additional 205 shares during the last quarter. Xponance Inc. increased its position in Exact Sciences by 1.8% in the 3rd quarter. Xponance Inc. now owns 13,073 shares of the medical research company’s stock worth $892,000 after buying an additional 235 shares during the period. Finally, Lido Advisors LLC lifted its holdings in shares of Exact Sciences by 4.4% during the third quarter. Lido Advisors LLC now owns 5,686 shares of the medical research company’s stock worth $388,000 after buying an additional 240 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on EXAS shares. TheStreet downgraded shares of Exact Sciences from a “c-” rating to a “d+” rating in a research note on Monday, February 26th. Canaccord Genuity Group decreased their price target on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Finally, Citigroup reiterated a “buy” rating and issued a $100.00 target price on shares of Exact Sciences in a research note on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $99.07.

Insider Buying and Selling

In other Exact Sciences news, EVP Sarah Condella sold 965 shares of Exact Sciences stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $59,279.95. Following the completion of the transaction, the executive vice president now owns 70,489 shares in the company, valued at approximately $4,330,139.27. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Jacob A. Orville sold 1,078 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $66,297.00. Following the transaction, the insider now directly owns 8,658 shares in the company, valued at $532,467. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sarah Condella sold 965 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total transaction of $59,279.95. Following the completion of the sale, the executive vice president now directly owns 70,489 shares of the company’s stock, valued at approximately $4,330,139.27. The disclosure for this sale can be found here. Insiders have sold a total of 70,611 shares of company stock worth $4,255,377 in the last three months. Insiders own 1.30% of the company’s stock.

Exact Sciences Stock Down 3.1 %

Shares of NASDAQ EXAS opened at $61.41 on Wednesday. The business has a fifty day moving average of $63.58 and a two-hundred day moving average of $64.69. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.07 and a current ratio of 2.32. Exact Sciences Co. has a 52-week low of $56.05 and a 52-week high of $100.77. The stock has a market cap of $11.29 billion, a PE ratio of -53.87 and a beta of 1.26.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.26. The firm had revenue of $646.89 million during the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period last year, the firm posted ($0.72) EPS. As a group, equities research analysts expect that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.